The ATR platform by Corryn Biotechnologies is set to revolutionise wound management by integrating a contactless, pain-free application process with bioresorbable, micro-structured synthetic materials which have been clinically validated to enhance wound healing. This innovative approach ensures efficient and painless dressing for even the most challenging wounds.

To date, Corryn Biotechnologies has demonstrated the ATR technology’s safety and usability in preclinical animal models and established a distinguished clinical advisory board to guide the platform’s transition to human trials in Q3 2025.

Dr Luke Burke completed his PhD at Swansea University in 2015 before going on to work for some of the most successful medical device multinational corporations, as well as various start-ups around Europe.